Cargando…
Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report
The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5–10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treat...
Autores principales: | Pokorska-Śpiewak, Maria, Dobrzeniecka, Anna, Ogrodnik, Agnieszka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407716/ https://www.ncbi.nlm.nih.gov/pubmed/36005263 http://dx.doi.org/10.3390/idr14040061 |
Ejemplares similares
-
The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2022) -
One-Year Outcomes after Ledipasvir/Sofosbuvir Treatment of Chronic Hepatitis C in Teenagers with and without Significant Liver Fibrosis—A Case Series Report
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2021) -
Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2021) -
Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O'Brien, Thomas R., et al.
Publicado: (2014) -
Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities
por: AbouBakr, Othman, et al.
Publicado: (2022)